» Articles » PMID: 19064638

Active and Passive Immunizations with Bordetella Colonization Factor A Protect Mice Against Respiratory Challenge with Bordetella Bronchiseptica

Overview
Journal Infect Immun
Date 2008 Dec 10
PMID 19064638
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Bordetella colonization factor A (BcfA) is an outer membrane immunogenic protein, which is critical for efficient colonization of the murine respiratory tract. These properties of BcfA prompted us to examine its utility in inducing a protective immune response against Bordetella bronchiseptica in a mouse model of intranasal infection. Mice vaccinated with BcfA demonstrated reduced pathology in the lungs and harbored lower bacterial burdens in the respiratory tract. Immunization with BcfA led to the generation of BcfA-specific antibodies in both the sera and lungs, and passive immunization led to the reduction of B. bronchiseptica in the tracheas and lungs. These results suggest that protection after immunization with BcfA is mediated in part by antibodies against BcfA. To further investigate the mechanism of BcfA-induced immune clearance, we examined the role of neutrophils and macrophages. Our results demonstrate that neutrophils are critical for anti-BcfA antibody-mediated clearance and that opsonization with anti-BcfA serum enhances phagocytosis of B. bronchiseptica by murine macrophages. We show that immunization with BcfA results in the production of gamma interferon and subclasses of immunoglobulin G antibodies that are consistent with the induction of a Th1-type immune response. In combination, our findings suggest that the mechanism of BcfA-mediated immunity involves humoral and cellular responses. Expression of BcfA is conserved among multiple clinical isolates of B. bronchiseptica. Our results demonstrate the striking protective efficacy of BcfA-mediated immunization, thereby highlighting its utility as a potential vaccine candidate. These results also provide a model for the development of cell-free vaccines against B. bronchiseptica.

Citing Articles

The adjuvant BcfA activates antigen presenting cells through TLR4 and supports T and T1 while attenuating T2 gene programming.

Shamseldin M, Read K, Hall J, Tuazon J, Brown J, Guo M Front Immunol. 2024; 15:1439418.

PMID: 39267766 PMC: 11390363. DOI: 10.3389/fimmu.2024.1439418.


Bacterial-viral interactions: a factor that facilitates transmission heterogeneities.

Stein R, Bianchini E FEMS Microbes. 2023; 3:xtac018.

PMID: 37332498 PMC: 10117881. DOI: 10.1093/femsmc/xtac018.


Systemic priming and intranasal booster with a BcfA-adjuvanted acellular pertussis vaccine generates CD4+ IL-17+ nasal tissue resident T cells and reduces nasal colonization.

Yount K, Hall J, Caution K, Shamseldin M, Guo M, Marion K Front Immunol. 2023; 14:1181876.

PMID: 37275891 PMC: 10232778. DOI: 10.3389/fimmu.2023.1181876.


spp. utilize the type 3 secretion system to manipulate the VIP/VPAC2 signaling and promote colonization and persistence of the three classical in the lower respiratory tract.

First N, Pedreira-Lopez J, San-Silvestre M, Parrish K, Lu X, Gestal M Front Cell Infect Microbiol. 2023; 13:1111502.

PMID: 37065208 PMC: 10090565. DOI: 10.3389/fcimb.2023.1111502.


Prime-Pull Immunization of Mice with a BcfA-Adjuvanted Vaccine Elicits Sustained Mucosal Immunity That Prevents SARS-CoV-2 Infection and Pathology.

Shamseldin M, Kenney A, Zani A, Evans J, Zeng C, Read K J Immunol. 2023; 210(9):1257-1271.

PMID: 36881867 PMC: 10121870. DOI: 10.4049/jimmunol.2200297.


References
1.
Stevenson A, Roberts M . Use of Bordetella bronchiseptica and Bordetella pertussis as live vaccines and vectors for heterologous antigens. FEMS Immunol Med Microbiol. 2003; 37(2-3):121-8. DOI: 10.1016/S0928-8244(03)00068-3. View

2.
Kirimanjeswara G, Mann P, Harvill E . Role of antibodies in immunity to Bordetella infections. Infect Immun. 2003; 71(4):1719-24. PMC: 152104. DOI: 10.1128/IAI.71.4.1719-1724.2003. View

3.
STAINER D, Scholte M . A simple chemically defined medium for the production of phase I Bordetella pertussis. J Gen Microbiol. 1970; 63(2):211-20. DOI: 10.1099/00221287-63-2-211. View

4.
Huang X, Lindler L . The pH 6 antigen is an antiphagocytic factor produced by Yersinia pestis independent of Yersinia outer proteins and capsule antigen. Infect Immun. 2004; 72(12):7212-9. PMC: 529099. DOI: 10.1128/IAI.72.12.7212-7219.2004. View

5.
Miller D, Ross E, Alderslade R, Bellman M, Rawson N . Pertussis immunisation and serious acute neurological illness in children. Br Med J (Clin Res Ed). 1981; 282(6276):1595-9. PMC: 1505512. DOI: 10.1136/bmj.282.6276.1595. View